Ivonescimab
Monoclonal antibody
Ivonescimab is a humanized bispecific monoclonal antibody currently being trialed for use against non-small-cell lung cancer. Developed by Akeso, it has been approved in China for the treatment of epidermal growth factor receptor-mutated locally advanced or metastatic non-squamous NSCLC in patients who have progressed past tyrosine kinase inhibitor therapy, and is undergoing clinical trials elsewhere.
01Mechanism of action
Ivonescimab prevents tumor proliferation and angiogenesis by inhibiting programmed cell death protein 1 and vascular endothelial growth factor A, respectively.
02Research
Ivonescimab so far has only completed trials in Chinese patients, and is currently undergoing phase III trials in the United States for the treatment of non-squamous non-small-cell lung cancer and advanced NSCLC.
03Society and culture
The initial success of ivonescimab in trials is compared to already-approved drugs such as Merck & Co.'s Keytruda (pembrolizumab); its success has been described as important for the pharmaceutical industry in China.
Sources and credits
This article is adapted from the Wikipedia article “Ivonescimab”, written by its contributors and licensed under CC BY-SA 4.0. Fathomly has changed the layout, removed citation markers, navigation and maintenance notices, and adjusted punctuation. This adapted version is shared under the same license. For references, see the original article.
Fathomly is not affiliated with or endorsed by the Wikimedia Foundation. Spotted a problem? Tell us.
